Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. Fall 2017;11(4):201-207.
doi: 10.15171/joddd.2017.036. Epub 2017 Dec 13.

Effects of Systemic Administration of HESA-A on the Expression of Cyclin D1 and EGFR and E-cadherin in the Induced Tongue Dysplasia in Rats

Affiliations
Free PMC article

Effects of Systemic Administration of HESA-A on the Expression of Cyclin D1 and EGFR and E-cadherin in the Induced Tongue Dysplasia in Rats

Shirin Fattahi et al. J Dent Res Dent Clin Dent Prospects. .
Free PMC article

Abstract

Background. HESA-A has herbal and marine bases, containing minerals and rare elements such as Zr, Cr, Ga, Mn, Mg, Ca, Sr, Cu, Ti, etc. Its mechanism of action includes antioxidant, antiinflammatory and adjustment of the immune system. The aim of this study was to evaluate the effects of HESA-A systemic drug on expression of cyclin D1, EGFR and E-cadherin in induced tongue dysplasia in rats. Methods. In this experimental study, the effects of the systemic drug HESA-A on the expression of cyclin D1, EGFR, and E-cadherin molecular markers were examined in induced tongue dysplasia in rats. Results. The incidence rate of cyclin D1 in groups receiving HESA-A was lower than the group that did not receive the drug (77.78% in the 0‒5% range versus 77.78% in the 5‒50% range). In the case of expression of E-cadherin in group D, which did not receive HESA-A, a decrease was observed in the expression of this cell adhesion marker as compared to the other two groups. The incidence of E-cadherin was dependent on HESA-A dose, while with 500 mg/kg it was higher than other groups (>75% in 55.55% versus >75% in 11.11%). Concerning the incidence of EGFR in all the three groups most cases were grade 0. Conclusion. The results of the present research indicated that considering changes in the expression of cyclin D1 and E-cadherin markers in groups treated with HESA-A, HESA-A® has preventive effects on development of cancer in dysplastic lesions through regulation of expression of these molecules.

Keywords: Biomarkers; EGFR protein; cadherin; carcinoma; rat; squamous cell carcinoma.

Figures

Figure 1
Figure 1
Figure 2
Figure 2
Figure 3
Figure 3
Chart 1‏
Chart 1‏
Chart 2.
Chart 2.
Chart 3
Chart 3

Similar articles

See all similar articles

References

    1. Bradbury KE, Appleby PN, Key TJ. Fruit, vegetable, and fiber intake in relation to cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC) Am J Clin Nutr. 2014;100(1):394–8‏. - PubMed
    1. Smith EM, Rubenstein LM, Haugen TH, Pawlita M, Turek LP. Complex etiology underlies risk and survival in head and neck cancer human papillomavirus, tobacco, and alcohol: a case for multifactor disease. J Clin Oncol. 2012;2012:571862. doi: 10.1155/2012/571862. - DOI - PMC - PubMed
    1. Chrysovergis A, Gorgoulis VG, Giotakis I, Tsiambas E, Karameris A, Kittas C. et al. Simultaneous over activation of EGFR, telomerase (h TERT), and cyclin D1 correlates with advanced disease in larynx squamous cell carcinoma: a tissue microarray analysis. Med Oncol. 2011;28:871–7. doi: 10.1007/s12032-010-9522-3. - DOI - PubMed
    1. Huang S-F, Cheng S-D, Chuang W-Y, Chen I-H, Liao C-T, Wang H-M. et al. Cyclin D1 overexpression and poor clinical outcomes in Taiwanese oral cavity squamous cell carcinoma. World J Surg Oncol. 2012;16(10):40. doi: 10.1186/1477-7819-10-40. - DOI - PMC - PubMed
    1. Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK, Batra SK. Targeting the EGFR signaling pathway in cancer therapy Expert opinion on therapeutic targets. Expert Opin Ther Targets. 2012;16(1):15–31. doi: 10.1517/14728222.2011.648617. - DOI - PMC - PubMed

LinkOut - more resources

Feedback